Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.
$36.18-1.09%
报价 2026-11-13
市值
$2.66B
EV
$2.59B
PE (TTM)
31.7x
预期 PE (FY2026)
27.5x
52 周区间距高点 -1.1%
$16.30$36.58
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 1.33 → 1.60（1.2x） | 22.7 |
| FY+32028-12 | 1.2x | 1.33 → 1.85（1.4x） | 19.5 |
毛利率 25% · TTM 收入 $1339M · 基数 EPS 1.33（调整后）
电话会信号
辅助标签Q3 20262026-11-04
需求加速上调指引
指引 上调
信心 5
分析师 4
“We expect to have more than 660 clients and 8.3 million covered lives in 2027.”
原文引用（2）
- 需求加速：our active pipeline... is bigger than it's ever been at this point in time, including over last year
- 上调指引：we're pleased to raise the midpoint of our guidance for the year
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PGNYProgyny, Inc. | $2.66B | -1.1% | +7.7% | 24.5% | 31.7x | 18.5x | 12.3x | |
| TXG10x Genomics, Inc. | $7.07B | -1.5% | -1.1% | 74.5% | – | 204.2x | 66.8x | |
| UFPTUFP Technologies, Inc. | $2.36B | -0.3% | +9.8% | 29.3% | 33.3x | 22.8x | 41.6x | |
| SDGRSchrödinger, Inc. | $1.95B | -4.3% | +0.8% | 59.3% | – | – | – | |
| OMCLOmnicell, Inc. | $1.61B | +0.2% | +3.8% | 44.8% | 36.5x | 10.1x | 11.3x | |
| TDOCTeladoc Health, Inc. | $1.6B | +1.3% | -4.0% | 68.6% | – | 7.6x | 7.0x | |
| ALVOAlvotech | $1.5B | -10.3% | +3.0% | 50.7% | – | – | – | |
| GDRXGoodRx Holdings, Inc. | $1.21B | +1.4% | +0.6% | 89.5% | 69.4x | 8.7x | 8.5x | |
| OMDAOmada Health | $889M | -2.5% | +35.4% | 75.9% | 169.6x | 40.3x | 32.8x | 高增长 |
| 同行中位数 | – | – | +1.9% | 63.9% | 52.9x | 16.4x | 22.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $341.3M | $350.5M | $328.5M | $318.4M | $313.3M | $332.9M | $324M | $298.4M |
| Gross Margin | 24.5% | 25.5% | 25.3% | 24.1% | 23.2% | 23.7% | 23.4% | 21.3% |
| Operating Margin | 10.3% | 11.4% | 10.8% | 4.8% | 6.9% | 7.3% | 7.5% | 5.3% |
| Net Income | $26.3M | $28.1M | $24.2M | $12.5M | $13.9M | $17.1M | $15.1M | $10.5M |
| Diluted EPS | 0.32 | 0.34 | 0.29 | 0.14 | 0.15 | 0.19 | 0.17 | 0.12 |
| Operating Cash Flow | $56.6M | $96.4M | $45.9M | $54.2M | $50.7M | $55.5M | $49.8M | $52.2M |